Additional file 1: of Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

Figure S1. Schematic representation of the therapeutic strategy. Figure S2. Schematic representation of lentiviral expression vector for E1A. Figure S3. Western blot analysis of CD3-HAC. Figure S4. Transduced MDA-MB-231 cells secreted CD3-HAC constantly. Figure S5. The expression of Perforin and Granzyme B of PBMC was measured in co-culture system. Figure S6. The expression of PD-1 on CD8+ cells was measured by flow cytometry after co-incubation with 231.CD3 for 3 days. Figure S7. The inhibitory curve of MDA-MB-231 cells treated with 5-FU. Figure S8. Intratumor injection of adenoviruses against the MDA-MB-231 cells xenograft tumors. Figure S9. Each fluorescence channel in Fig. 6a. Figure S10. Immunohistochemical analysis of the lung. Figure S11. Dual viruses infected MCSs causing no detectable side effects in vivo. Table S1. Primary antibodies. Table S2. Secondary antibodies. (DOCX 129760 kb